Xenothera Sas
Clinical trials sponsored by Xenothera Sas, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new antibody outsmart advanced solid tumors? Results expected Dec 2026 (estimated)
- Can a new antibody outsmart Hard-to-Treat blood cancer? Results expected Dec 2026 (estimated)
-
Can a new antibody outsmart advanced solid tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called XON7 in people with advanced or metastatic solid tumors who have no effective standard treatment left. XON7 is a specially engineered antibody designed to attack cancer cells, given through an IV. The study has two parts: first, t…
Phase 1/2 • Sponsor: Xenothera SAS • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a new antibody outsmart Hard-to-Treat blood cancer?
Disease control Recruiting nowThis trial is testing an experimental drug called LIS1, a specially engineered antibody designed to target and attack cancerous T cells. It is for adults with peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatments. The study has two parts: fi…
Phase 1/2 • Sponsor: Xenothera SAS • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC